Screening for lung cancer has been utilized for several decades without demonstrating overall survival benefit. However, recent advances in treatment of lung cancer, improvements in our biologic understanding of lung cancer development, and an increasing population of healthy ex-smokers provide cause for optimism. Several chemoprevention trials suggest that it may be possible to intervene in the oncologic process prior to the development of invasive malignancy, resulting in a delay or reversal of these changes.
Get full access to this article
View all access options for this article.
References
1.
ResnicowK., KabatG., WynderE.Progress in decreasing cigarette smoking. Important Adv Oncol.1991: 205–213.
2.
HalpernM.T., GillespieB.W., WarnerK.E.Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst.1993; 85: 457–464.
3.
KerrK.M., LambD.A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma. Br J Cancer.1988; 58: 419–422.
4.
FeinsteinA.R., SosinD.M., WellsC.K.The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med.1985; 312: 1604–1608.
5.
ShepherdF.A.Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol.1993; 5: 310–322.
6.
MountainC.F.Prognostic implications of the international staging system for lung cancer. Semin Oncol.1988; 15: 236–245.
7.
RothJ.A., FossellaF., KomakiR.A randomized trial comparing perioperative chemotherapy with surgery and surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst.1994; 86: 673–680.
8.
FeldR., RubinsteinL., ThomasP.A.Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst.1993; 85: 299–306.
9.
TockmanM.S., ErozanY.S., GuptaP.The early detection of second primary lung cancers by sputum immunostaining. Chest.1994; 106(Suppl 6): 385s–390s.
10.
MackayJ.US tobacco export to third world: third world war. Monogr Natl Cancer Inst.1992; 12: 25–28.
11.
LubinJ.H., BlotW.J.Lung cancer and smoking cessation: patterns of risk. J Natl Cancer Inst.1993; 85: 422–423.
12.
MulshineJ.L., LinnoilaR.I., TrestonA.M.Candidate biomarkers for application as intermediate end points of lung carcinogenesis. J Cell Biochem (Supplement).1992; 16G: 183–186.
13.
DevesaS.S., ShawG.L., BlotW.J.Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev.1991; 1: 29–34.
14.
BoucotK., HorieU., SokoloffM.Lung cancer detected by survey methods. Am J Public Health.1959; 49: 793–799.
15.
BrettG.Bronchial carcinoma in men deteccted by selective and unselective miniature radiography. A review of 228 cases. Tubercle.1959; 40: 192–195.
16.
NashF.A., MorganJ.M., TomkinsJ.G.South London Lung Cancer Study. Br Med J.1968; 2: 715–721.
17.
SandersonD.Lung cancer screening: The Mayo study. Chest (Supplement).1986; 89: 324s.
18.
TockmanM.Survival and mortality from lung cancer in a screened population. Chest.1986; 89(Suppl 4): 324s–325s.
19.
MartiniN.Results of the Memorial Sloan-Kettering study in screening for early lung cancer. Chest.1986; 89(Suppl 4): 325s.
20.
KubikA., ParkinD.M., KhlatM.Lack of benefit fromsemi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer.1990; 45: 26–33.
21.
MillerA.Lung cancer screening: summary. Chest.1986; 89(Suppl 4): 325s–326s.
22.
EddyD.Screening for lung cancer. Ann Intern Med.1989; 111: 232–237.
23.
RodenhuisS., SlebosR.J.Clinical significance of ras oncogene activation in human lung cancer. Cancer Res.1992; 52(Suppl 9): 2665s–2669s.
24.
SidranskiD., TokinoT., HamiltonS.R.Identification of ras oncogene mutations in the stool of patients with curable colorectal tumor. Science.1992; 256: 102–105.
25.
TobiM., LuoF.C., RonaiZ.Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. J Natl Cancer Inst.1994; 86: 1007–1010.
26.
TadaM., OmataM., KawaiS.Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res.1993; 53: 2472–2474.
27.
CaldasC., HahnS., HrubanR.H.Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res.1995. In press.
28.
KellyK.Evaluation of k-ras mutations in sputum samples by single-stranded conformation polymorphism. Lung Cancer.1994; 11(Suppl 1): 225. Abstract.
29.
MillsN.E., FishmanC.L., ScholesJ.Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst.1995; 87: 1056–1060.
30.
MaoL., HrubanR.L., BoyleJ.O.Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res.1994; 54: 1634–1637.
31.
SorensonG., PribishD., MaurerL.Detection of mutated k-ras sequences in blood from patients with pulmonary carcinoma. Lung Cancer.1994; 11(Suppl 1): 57. Abstract.
32.
MulshineJ., TockmanM., ScottF.Global strategies for the early detection of epithelial cancers. In: SrivastavaS., ed. Early Detection of Cancer: Molecular Markers.Armonk, NY: Futura Publishing Co; 1994.
33.
RuckdeschelJ.Cellular characterization of lung cancer: a caveat. Chest.1993; 104: 331.
34.
HansenM., PedersenA.Tumor markers in patients with lung cancer. Chest (Supplement).1986; 89(Suppl 4): 219s–224s.
35.
MiyakeY., KodamaT., YamaguchiK.Progastrin-releasing peptide (31–98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res.1994; 54: 2136–2140.
36.
AguayoS., TalmadgeE.Jr, KaneM.Urinary levels of bombesin-like peptides in asymptomatic cigarette smokers: a potenttal risk marker for smoking related diseases. Cancer Res.1992; 52(suppl): 2727s–2731s.
37.
SpeirsC.J., MurrayS., DaviesD.S.Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol.1990; 29: 101–109.
38.
ShawG.L., FalkR.T., TuckerM.A.Debrisoquine metabolism and lung cancer risk. Proc Annu Meet Am Assoc Cancer Res.1994; 35: 1753a.
39.
SpitzM.R., HoqueA., TriznaZ.Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst.1994; 86: 1681–1684.
40.
OldenK.Mutagen hypersensitivity as a biomarker of genetic predisposition to carcinogenesis. J Natl Cancer Inst.1994; 86: 1660–1661.
41.
TockmanM.S., GuptaP.K., MyersJ.D.Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol.1988; 6: 1685–1693.
42.
TockmanM.S., GuptaP.K., PressmanN.J.Considerations in bringing a cancer biomarker to clinical application. Cancer Res.1992; 52(Suppl 9): 2711s–2718s.
43.
TockmanM., GuptaP., PressmanN.An approach to the clinical application of a lung cancer biomarker. In: SrivastavaS., ed. Early Detection of Cancer: Molecular Markers.Armonk, NY: Futura Publishing Co; 1994.
44.
HungJ., LamS., LeRicheJ.C.Autofluorescence of normal and malignant bronchial tissue. Lasers Surg Med.1991; 11: 99–105.
45.
LamS., MacAulayC., HungJ.Detection of dysplasia and carcinoma in situ by a lung imaging fluorescence endoscope (LIFE) device. Lasers Surg Med.1992; 12: 40.
46.
HeyneK.H., LipmmanS.M., LeeJ.J.The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol.1992; 10: 1519–1524. 47. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323: 795–801.
47.
PastorinoU., InfanteM., MaioliM.Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol.1993; 11: 1216–1222.
48.
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med.1994; 330: 1029–1035.
49.
LeeJ.S., LippmanS.M., BennerS.E.Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol.1994; 12: 937–945. Table 1. - Stage Distribution of Lung Cancer at Presentation
